Loading
A phase 1/2 trial of Emi-Le in triple-negative breast cancer, endometrial cancer, ovarian cancer and salivary gland cancers, run by Day One Biopharmaceuticals, Inc., now recruiting.
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT05377996 by Day One Biopharmaceuticals, Inc., with 360 participants planned, started 2022-08-15 and due to reach its primary completion in 2027-02. Interventions recorded: Emi-Le.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Endometrial cancer, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Day One Biopharmaceuticals and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Shares Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Endometrial cancer, Ovarian cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/